PRR11 and neoplasm: In subcutaneous tumor-bearing experiments, treatment with the SC79 reversed the PRR11 knockdown-induced reductions in tumor volume and weight (Figure 8B-C and Figure S12B), further supporting the establishment of the PRR11-AKT axis.